KCA
Search
- Page Path
- HOME > Search
Original Article
- Breast cancer
- Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
- Yoon Ju Bang, Won Kyung Kwon, Seok Jin Nam, Seok Won Kim, Byung-Joo Chae, Se Kyung Lee, Jai Min Ryu, Jong-Won Kim, Jonghan Yu, Jeong Eon Lee
- Cancer Res Treat. 2022;54(3):827-833. Published online October 13, 2021
- DOI: https://doi.org/10.4143/crt.2021.791
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Double heterozygosity (DH) for BRCA1 and BRCA2 variant is very rare with only a few cases reported, and most those in Caucasians. In this article, we present seven unrelated cases of DH for BRCA1/2 identified from a single institution in Korea, and describe the characteristics and phenotype of DH individuals compared to those with a single BRCA variant.
Materials and Methods
This study included 27,678 patients diagnosed with breast cancer and surgically treated at Samsung Medical Center (SMC) between January 2008 and June 2020. In total, 4,215 high-risk breast cancer patients were tested for the BRCA1/2 genes, and electronic medical records from 456 cases with pathogenic/likely pathogenic variants (PVs/LPVs) were reviewed.
Results
A younger mean age at diagnosis was associated with DH than a single variant of BRCA1/2. More triple-negative breast cancer (TNBC) and higher nuclear and histologic grade cancer occurred with DH than BRCA2 variant. All 7 cases of DH were unrelated, and their mutation combinations were different. There were no Ashkenazi founder variants detected.
Conclusion
We suggest that patients with DH for BRCA1/2 variants develop breast cancer at a younger age, but the histopathologic features are similar to those of BRCA1. -
Citations
Citations to this article as recorded by
- Multi-locus inherited neoplasia alleles syndromes in cancer: implications for clinical practice
Jeanette Yuen, Siqin Zhou, Rebecca Caeser, Mallika Venkatramani, Diana Nur Bte Ishak, Shao-Tzu Li, Zewen Zhang, Jianbang Chiang, Sock Hoai Chan, Joanne Ngeow
European Journal of Human Genetics.2025; 33(3): 289. CrossRef - Carcinoma erysipeloides secondary to male breast cancer in a patient with BRCA1 and BRCA2 mutations: a clinical presentation and management
Ayushya Ajmani, Daniel W Witheiler, Dario Kivelevitch
BMJ Case Reports.2025; 18(4): e264429. CrossRef - Double heterozygosity for BRCA1 and BRCA2 in breast cancer: considerations in surveillance and cancer risk management
Nonoko Wakaki, Tatsunori Shimoi, Shogo Nakamoto, Yuichiro Kikawa, Aki Ito, Takayuki Iwamoto
BMJ Case Reports.2025; 18(4): e263687. CrossRef - Two-hit events occurred independently in bilateral breast cancers in a germline double heterozygous carrier for BRCA1 and BRCA2
Ryoko Semba, Hidetaka Eguchi, Mizuki Takatsu, Toko Hashizume, Hideaki Moteki, Kazuma Maeno, Fumi Murakami, Junichiro Watanabe, Goro Kutomi, Masami Arai
Breast Cancer.2025; 32(6): 1472. CrossRef - Prevalence of MUTYH Monoallelic Variants in Patients With Hereditary Cancer Using Multigene Panel Testing
Gemma Caliendo, Chiara Della Pepa, Alessia Mignano, Luisa Albanese, Luana Passariello, Anna Cozzolino, Francesca Iengo, Anna Maria Molinari, Laura Pesce, Maria Teresa Vietri
Cancer Medicine.2025;[Epub] CrossRef - Clinicopathological features of Chinese ovarian cancer patients with double heterozygosity for cancer-predisposed genes
Yikun Jin, Wenyan Wang, Manqi Wu, Yiming Fan, Tongxia Wang, Cuiyu Huang, Tong Gao, Yan Liu, Yuan Li, Qiyu Liu, Hongyan Guo
BMC Cancer.2025;[Epub] CrossRef - Case Report: Clinical impact of BRCA1 and BRIP1 vs. BRCA1 and BRCA2 germline double heterozygosity in ovarian cancer: a comparative case study
Limei Zheng, Qianyuan Zhu, Fenglan Zhang, Hao Qiu, Lan Qin, Jianhua Yang, Ming Qi
Frontiers in Oncology.2025;[Epub] CrossRef - Double Pathogenic or Likely Pathogenic Variants in Cancer Predisposition Genes in Hungarian Cancer Patients
Tímea Pócza, János Papp, Anikó Bozsik, Vince Kornél Grolmusz, Petra Nagy, Attila Patócs, Henriett Butz
International Journal of Molecular Sciences.2025; 26(17): 8390. CrossRef - Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
Junjie Pan, Ning Ren, Lanqi Ren, YiBei Yang, Qiaoping Xu
Scientific Reports.2024;[Epub] CrossRef - Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants
Song Wen, Meng Zhang, Jiuan Chen, Li Hu, Jie Sun, Lu Yao, Ye Xu, Juan Zhang, Yuntao Xie
Breast Cancer Research and Treatment.2024; 208(1): 155. CrossRef - Discovery of BRCA1/BRCA2 founder variants by haplotype analysis
Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim
Cancer Genetics.2022; 266-267: 19. CrossRef
- Multi-locus inherited neoplasia alleles syndromes in cancer: implications for clinical practice
- 8,550 View
- 265 Download
- 11 Web of Science
- 11 Crossref
First
Prev
